The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Benjamin H. Mullish, Mohammed Nabil Quraishi, Jonathan P. Segal, Victoria L. McCune, Melissa Baxter, Gemma L. Marsden, David J. Moore, Alaric Colville, Neeraj Bhala, Tariq H. Iqbal, Christopher Settle, Graziella Kontkowski, Ailsa L. Hart, Peter Hawkey, Simon D. Goldenberg, Horace R.T. Williams*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

161 Citations (Scopus)

Abstract

Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the UK have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.

Original languageEnglish
Pages (from-to)1920-1941
Number of pages22
JournalGut
Volume67
Issue number11
DOIs
Publication statusPublished - 1 Nov 2018

Bibliographical note

Funding Information:
Competing interests THI acted as a consultant, advisor or speaker for Pharmacosmos and Shield Therapeutics. ALH acted as a consultant, advisory board member or speaker for AbbVie, Atlantic, Bristol-Myers Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. ALH also serves on the Global Steering Committee for Genentech. SDG received consultancy fees, speaker fees and research grant support from Astellas between 2015 and 2017; received consultancy fees and speaker fees from MSD between 2015 and 2017; and received consultancy fees in 2017 from Pfizer.

Funding Information:
funding There was no external funding for this work. BHM is the recipient of a Medical Research Council Clinical Research Training Fellowship (grant reference: MR/R000875/1). BHM and HRTW receive support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London.

Publisher Copyright:
© Author(s) 2018.

Keywords

  • colonic microflora
  • enteric bacterial microflora
  • infective colitis
  • inflammatory bowel disease
  • intestinal microbiology

Fingerprint

Dive into the research topics of 'The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines'. Together they form a unique fingerprint.

Cite this